Renoprotective effect of long-term combined treatment with adrenomedullin and omapatrilat in hypertensive rats

Journal of Hypertension

Volumn 23, Issue 12, 2005, Pages 2287-2296

  Ishimura, Kimihiko ^a   Nishikimi, Toshio ^a   Akimoto, Kazumi ^a   Ono, Hidehiko ^a   Kangawa, Kenji ^b   Matsuoka, Hiroaki ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Adrenomedullin; Extracellular matrix; Hypertension; Neutral end peptidase NADPH oxidase; Omapatrilat; Renoprotective

Indexed keywords

ADRENOMEDULLIN; ATRIAL NATRIURETIC FACTOR; COLLAGEN TYPE 1; COLLAGEN TYPE 3; GLYCOPROTEIN GP 91; MESSENGER RNA; NEUROHORMONE; OMAPATRILAT; PROTEIN P40; PROTEIN P47; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TRANSFORMING GROWTH FACTOR BETA; VASOPEPTIDASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GENE EXPRESSION; HISTOLOGY; HYPERTENSION; KIDNEY CORTEX; KIDNEY FUNCTION; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; SYSTOLIC BLOOD PRESSURE;

EID: 27944437492     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000188731.75592.eb     Document Type: Article

References (36)

1. Ichiki Y, Kitamura K, Kangawa K, Kawamoto M, Matsuo H, Eto T. Distribution and characterization of immunoreactive adrenomedullin in human tissue and plasma. FEBS Lett 1994; 338:6-10.
2. Owji AA, Smith DM, Coppoock HA, Morgan DG, Bhogal R, Ghatei MA, et al. An abundant specific binding site for the novel vasodilator adrenomedullin in the rat. Endocrinology 1995; 136:2127-2134.
3. Ebara T, Miura K, Okumura M, Matsuura T, Kim S, Yukimura T, et al. Effect of adrenomedullin on renal hemodynamics and functions in dogs. Eur J Pharmacol 1994; 263:69-73.
4. Parameswaran N, Nambi P, Hall CS, Brooks DP, Spielman WS. Adrenomedullin decreases extracellular signal-regulated kinase activity through an increase in protein phosphatase-2A activity in mesangial cells. Eur J Pharmacol 2000; 388:133-138.
5. Jiang W, Yang JH, Pan CS, Qi YF, Pang YZ, Tang CS. Effects of adrenomedullin on cell proliferation in rat adventitia induced by aldosterone. J Hypertens 2004; 22:1953-1961.
6. Niu P, Shindo T, Iwata H, Iimuro S, Takeda N, Zhang Y, et al. Protective effects of endogenous adrenomedullin on cardiac hypertrophy, fibrosis, and renal damage. Circulation 2004; 109:1789-1794.
7. Sata M, Kakoki M, Nagata D, Nishimatsu H, Suzuki E, Aoyagi T, et al. Adrenomedullin and nitric oxide inhibit human endothelial cell apoptosis via a cyclic GMP-independent mechanism. Hypertension 2000; 36:83-88.
8. Okumura H, Nagaya N, Itoh T, Okano I, Hino J, Mori K, et al. Adrenomedullin infusion attenuates myocardial ischemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway. Circulation 2004; 109:242-248.
9. Ishimitsu T, Nishikimi T, Saito Y, Kitamura K, Eto T, Kangawa K, et al. Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure. J Clin Invest 1994; 94:2158-2161.
10. Nishikimi T, Horio T, Kohmoto Y, Yoshihara F, Nagaya N, Inenaga T, et al. Molecular forms of plasma and urinary adrenomedullin in normal, essential hypertension and chronic renal failure. J Hypertens 2001; 19:765-773.
11. Kato J, Kitamura K, Matsui E, Tanaka M, Ishizaka Y, Kita T, et al. Plasma adrenomedullin and natriuretic peptides in patients with essential or malignant hypertension. Hypertens Res 1999; 22:61-65.
12. Nishikimi T, Mori Y, Kobayashi N, Tadokoro K, Wang X, Akimoto K, et al. Renoprotective effect of chronic adrenomedullin infusion in Dahl salt-sensitive rats. Hypertension 2002; 39:1077-1082.
13. Mori Y, Nishikimi T, Kobayashi N, Ono H, Kangawa K, Matsuoka H. Long-term adrenomedullin infusion improves survival in malignant hypertensive rats. Hypertension 2002; 40:107-113.
14. Jiang W, Jiang HF, Pan CS, Cai DY, Qi YF, Pang YZ, et al. Relationship between the contents of adrenomedullin and distributions of neutral endopeptidase in blood and tissues of spontaneously hypertensive rats. Hypertens Res 2004; 27:109-117.
15. Lisy O, Jougasaki M, Schirger JA, Chen HH, Barclay PT, Burnett JC Jr. Neutral endopeptidase inhibition potentiates the natriuretic actions of adrenomedullin. Am J Physiol 1998; 275:F410-F414.
16. Rademaker MT, Charles CJ, Cooper GJ, Coy DH, Espiner EA, Lewis LK, et al. Combined endopeptidase inhibition and adrenomedullin in sheep with experimental heart failure. Hypertension 2002; 39:93-98.
17. Sagnella GA. Vasopeptidase inhibitors. J Ren Angiotens Aldosterone Syst 2002; 3:90-95.
18. Chini EN, Chini CC, Bolliger C, Jougasaki M, Grande JP, Burnett JC Jr, et al. Cytoprotective effects of adrenomedullin in glomerular cell injury: central role of cAMP signaling pathway. Kidney Int 1997; 52:917-925.
19. Shimosawa T, Shibagaki Y, Ishibashi K, Kitamura K, Kangawa K, Kato S, et al. Adrenomedullin, an endogenous peptide, counteracts cardiovascular damage. Circulation 2002; 105:106-111.
20. Nishikimi T, Yoshihara F, Horinaka S, Kobayashi N, Mori Y, Tadokoro K, et al. Chronic administration of adrenomedullin attenuates transition from left ventricular hypertrophy to heart failure in rats. Hypertension 2003; 42:1034-1041.
21. Ohta H, Tsuji T, Asai S, Tanizaki S, Sasakura K, Teraoka H, et al. A simple immunoradiometric assay for measuring the entire molecules of adrenomedullin in human plasma. Clin Chim Acta 1999; 287:131-143.
22. Nagaya N, Nishikimi T, Horio T, Yoshihara F, Kanazawa A, Matsuo H, et al. Cardiovascular and renal effects of adrenomedullin in rats with heart failure. Am J Physiol 1999; 276:R213-R218.
23. Nishikimi T, Tadokoro K, Mori Y, Wang X, Akimoto K, Yoshihara F, et al. Ventricular adrenomedullin system in the transition from LVH to heart failure in rats. Hypertension 2003; 41:512-518.
24. Nishikimi T, Horio T, Sasaki T, Yoshihara F, Takishita S, Miyata A, et al. Cardiac production and secretion of adrenomedullin are increased in heart failure. Hypertension 1997; 30:1369-1375.
25. Nishikimi T, Miyata A, Horio T, Yoshihara F, Nagaya N, Takishita S, et al. Urocortin, a member of the corticotropin-releasing factor family, in normal and diseased heart. Am J Physiol Heart Circ Physiol 2000; 279:H3031-H3039.
26. Ying L, Flamant M, Vandermeersch S, Boffa JJ, Chatziantoniou C, Dussaule JC, et al. Renal effects of omapatrilat and captopril in salt-loaded, nitric oxide-deficient rats. Hypertension 2003; 42:937-944.
27. Corti R, Burnett JC Jr, Rouleau JL, Ruschitzka F, Luscher TF. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation 2001; 104:1856-1862.
28. Kubota E, Dean RG, Hubner RA, Balding LC, Johnston CI, Burrell LM. Evidence for cardioprotective, renoprotective, and vasculoprotective effects of vasopeptidase inhibitors in disease. Curr Hypertens Rep 2001; 3(Suppl. 2):S31-S33.
29. Dobrzynski E, Wang C, Chao J, Chao L. Adrenomedullin gene delivery attenuates hypertension, cardiac remodeling, and renal injury in deoxycorticosterone acetate-salt hypertensive rats. Hypertension 2000; 36:995-1001.
30. Zhang JJ, Yoshida H, Chao L, Chao J. Human adrenomedullin gene delivery protects against cardiac hypertrophy, fibrosis, and renal damage in hypertensive dahl salt-sensitive rats. Hum Gene Ther 2000; 11:1817-1827.
31. Wang C, Dobrzynski E, Chao J, Chao L. Adrenomedullin gene delivery attenuates renal damage and cardiac hypertrophy in Goldblatt hypertensive rats. Am J Physiol Renal Physiol 2002; 280:F964-F971.
32. Vaziri ND. Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Curr Opin Nephrol Hypertens 2004; 13:93-99.
33. Iglesias-De La Cruz MC, Ruiz-Torres P, Alcami J, Diez-Marques L, Ortega-Velazquez R, Chen S, et al. Hydrogen peroxide increases extracellular matrix mRNA through TGF-beta in human mesangial cells. Kidney Int 2001; 59:87-95.
34. Meng S, Cason GW, Gannon AW, Racusen LC, Manning RD Jr. Oxidative stress in Dahl salt-sensitive hypertension. Hypertension 2003; 41:1346-1352.
35. Kawai J, Ando K, Shimosawa T, Harii K, Fujita T. Regional hemodynamic effects of adrenomedullin in Wistar rats: a comparison with calcitonin gene-related peptide. Hypertens Res 2002; 25:441-446.
36. McGregor DO, Troughton RW, Frampton C, Lynn KL, Yandle T, Richards AM, et al. Hypotensive and natriuretic actions of adrenomedullin in subjects with chronic renal impairment. Hypertension 2001; 37:1279-1284.